Andrew D Weinberg
Overview
Explore the profile of Andrew D Weinberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
3054
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yu G, Li Y, Cui Z, Morris N, Weinberg A, Fox B, et al.
Sci Rep
. 2016 Nov;
6:37558.
PMID: 27874054
It is well-known that vaccines comprising of irradiated whole tumor cells or tumor-derived heat shock proteins can generate tumor-specific immune responses. In contrast, we showed recently that vaccines composed of...
12.
Bryan R, Gough M, Seung S, Jutric Z, Weinberg A, Fox B, et al.
Oral Oncol
. 2016 Sep;
61:166-76.
PMID: 27614589
Cytoreductive surgery is an approach to cancer treatment that aims to reduce the number of cancer cells via resection of primary tumor or metastatic deposits, in an effort to minimize...
13.
Moran A, Polesso F, Weinberg A
J Immunol
. 2016 Aug;
197(6):2509-21.
PMID: 27503208
Cancer cells harbor high-affinity tumor-associated Ags capable of eliciting potent antitumor T cell responses, yet detecting these polyclonal T cells is challenging. Therefore, surrogate markers of T cell activation such...
14.
Bell R, Leidner R, Crittenden M, Curti B, Feng Z, Montler R, et al.
Oral Oncol
. 2015 Nov;
52:1-10.
PMID: 26614363
OX40 is a member of the tumor necrosis factor (TNF) receptor family and a potent co-stimulatory pathway that when triggered can enhance T-cell memory, proliferation and anti-tumor activity in patients...
15.
Triplett T, Tucker C, Triplett K, Alderman Z, Sun L, Ling L, et al.
Cancer Immunol Res
. 2015 Jan;
3(5):526-35.
PMID: 25627655
In preclinical tumor models, αOX40 therapy is often successful at treating small tumors, but is less effective once the tumors become large. For a tumor immunotherapy to be successful to...
16.
Kovacsovics-Bankowski M, Chisholm L, Vercellini J, Tucker C, Montler R, Haley D, et al.
J Immunother Cancer
. 2014 Dec;
2(1):38.
PMID: 25436113
Background: We examined the phenotype and function of lymphocytes collected from the peripheral blood (PBL) and tumor (TIL) of patients with two different solid malignancies: colorectal cancer liver metastases (CRLM)...
17.
Farazi M, Cohn Z, Nguyen J, Weinberg A, Ruby C
J Leukoc Biol
. 2014 Apr;
96(2):245-54.
PMID: 24714553
Decline in CD4 T cell immune responses is associated with aging. Although a number of immunological defects have been identified in elderly mice (>18 months old), a key early-onset immune...
18.
Farazi M, Nguyen J, Goldufsky J, Linnane S, Lukaesko L, Weinberg A, et al.
Cancer Immunol Immunother
. 2014 Apr;
63(6):615-26.
PMID: 24682539
Immune responses wane during aging, posing challenges to the potential effectiveness of cancer immunotherapies. We previously demonstrated that in the context of a promising immunotherapeutic, OX40 agonist (αOX40), older animals...
19.
Curti B, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, et al.
Cancer Res
. 2013 Nov;
73(24):7189-7198.
PMID: 24177180
OX40 is a potent costimulatory receptor that can potentiate T-cell receptor signaling on the surface of T lymphocytes, leading to their activation by a specifically recognized antigen. In particular, OX40...
20.
Moran A, Kovacsovics-Bankowski M, Weinberg A
Curr Opin Immunol
. 2013 Feb;
25(2):230-7.
PMID: 23414607
T cell-mediated rejection of tumors requires signals from the T cell receptor and co-stimulatory molecules to license effector functions of tumor-antigen specific T cells. There is also an array of...